UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2023 (
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File No.) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On December 30, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), closed the transactions contemplated by that certain Purchase and Sale Agreement dated December 20, 2022 by and between the Company and HCR. At the closing, the Company recorded $31,000,000, net of certain transaction costs, as a royalty financing liability.
The information set forth in Item 1.01 of the Current Report on Form 8-K filed December 20, 2022 is incorporated by reference into this Item 2.03 of this Current Report on Form 8-K.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Atara Biotherapeutics, Inc. | ||
| By: | /s/ Amar Murugan | |
| Amar Murugan | ||
| Senior Vice President, General Counsel | ||
Dated: January 6, 2023
3
Document and Entity Information |
Dec. 30, 2022 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001604464 |
| Document Type | 8-K |
| Document Period End Date | Dec. 30, 2022 |
| Entity Registrant Name | ATARA BIOTHERAPEUTICS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-36548 |
| Entity Tax Identification Number | 46-0920988 |
| Entity Address, Address Line One | 2380 Conejo Spectrum Street |
| Entity Address, Address Line Two | Suite 200 |
| Entity Address, City or Town | Thousand Oaks |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 91320 |
| City Area Code | (805) |
| Local Phone Number | 623-4211 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.0001 per share |
| Trading Symbol | ATRA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |